Goldman Sachs Group Inc Corbus Pharmaceuticals Holdings, Inc. Transaction History

Goldman Sachs Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 May 14, 2024	SELL	$0.17 - $5.31 $1,216 - $37,993	-7,155 Reduced 7.47%	88,583 $15,000
Q3 2022 Nov 10, 2022	SELL	$0.17 - $5.31 $1,216 - $37,993	-7,155 Reduced 7.47%	88,583 $0
Q2 2022 May 14, 2024	BUY	$0.21 - $0.53 $20,104 - $50,741	95,738 New	95,738 $24,000
Q2 2022 Aug 15, 2022	BUY	$0.21 - $0.53 $20,104 - $50,741	95,738 New	95,738 $24,000
Q1 2022 May 16, 2022	SELL	$0.32 - $0.67 $27,357 - $57,278	-85,491 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$0.6 - $1.11 $42,737 - $79,064	-71,229 Reduced 45.45%	85,491 $53,000
Q3 2021 Nov 10, 2021	BUY	$1.01 - $1.82 $158,287 - $285,230	156,720 New	156,720 $160,000

38.7K

Ticker CRBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,268,000
Market Cap $1.22B
Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.